Sandoz Inc. v. Amgen Inc.: Supreme Court Clarifies BPCIA Provisions








On June 12, 2017, the United States Supreme Court issued its first ruling on two key provisions of the Biologics Price Competition and Innovation Act (“BPCIA”) concerning the resolution of patent infringement suits in connection with the submission to the Food and Drug Administration (“FDA”) of applications to commercialize biosimilars in the United States.1

To view the entire article please visit here.

0 views

Recent Posts

See All

© Law Exchange International 2020

Web Design by

Web and Graphic Design near Grand Rapids

Contact

David Lindgren

secretary@lawexchange.org

Shakespeare House

42 Newmarket Road

Cambridge CB5 8EP

England

Connect with LEI

  • White Facebook Icon
  • White Twitter Icon
  • White LinkedIn Icon

Add on Facebook

Add on Twitter

Add on LinkedIn